Key Points
- Equillium insider Penny Tom sold 65,000 shares on May 28 at an average price of $2.95, totaling about $191,750. The sale was made under a pre-arranged Rule 10b5-1 plan, and it cut the insider’s position by 50%.
- Analyst sentiment is turning more bullish, with Leerink Partners upgrading Equillium to outperform and Roth Mkm reiterating a buy rating with a $12 price target. Overall, MarketBeat reports a consensus rating of Moderate Buy and an average target price of $7.57.
- The stock has shown recent strength despite mixed fundamentals, opening at $2.90 and trading near its 52-week high of $3.10 after a 2.1% rise. However, the company recently reported an EPS miss and still expects a full-year loss.
Equillium, Inc. (NASDAQ:EQ - Get Free Report) COO Christine Zedelmayer sold 9,821 shares of the business's stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $2.70, for a total transaction of $26,516.70. Following the sale, the chief operating officer owned 62,586 shares in the company, valued at $168,982.20. This represents a 13.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christine Zedelmayer also recently made the following trade(s):
- On Thursday, May 28th, Christine Zedelmayer sold 86,012 shares of Equillium stock. The shares were sold at an average price of $2.80, for a total transaction of $240,833.60.
- On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The shares were sold at an average price of $2.50, for a total transaction of $300,780.00.
- On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The shares were sold at an average price of $2.00, for a total transaction of $362,438.00.
Equillium Stock Performance
Equillium stock opened at $2.90 on Friday. The firm has a market cap of $183.36 million, a PE ratio of -9.06 and a beta of 1.67. The firm's 50 day moving average price is $2.11 and its two-hundred day moving average price is $1.64. Equillium, Inc. has a twelve month low of $0.27 and a twelve month high of $3.10.
Equillium (NASDAQ:EQ - Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Equities analysts anticipate that Equillium, Inc. will post -0.24 EPS for the current fiscal year.
Institutional Trading of Equillium
A number of hedge funds have recently bought and sold shares of EQ. Dimensional Fund Advisors LP acquired a new position in shares of Equillium in the 1st quarter valued at $31,000. Virtu Financial LLC raised its stake in shares of Equillium by 133.4% in the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company's stock valued at $34,000 after buying an additional 13,591 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Equillium in the 3rd quarter valued at $35,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Equillium in the 1st quarter valued at $100,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Equillium in the 3rd quarter valued at $99,000. 27.05% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several research firms recently issued reports on EQ. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Equillium in a report on Friday, March 27th. B. Riley Financial began coverage on shares of Equillium in a report on Thursday, April 16th. They set a "buy" rating and a $6.00 price objective for the company. Oppenheimer began coverage on shares of Equillium in a report on Thursday, April 23rd. They set an "outperform" rating and a $7.00 price objective for the company. Zacks Research raised shares of Equillium to a "hold" rating in a report on Thursday, February 26th. Finally, Cantor Fitzgerald began coverage on shares of Equillium in a report on Tuesday, April 7th. They issued an "overweight" rating and a $10.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $7.57.
Read Our Latest Stock Analysis on Equillium
Key Headlines Impacting Equillium
Here are the key news stories impacting Equillium this week:
- Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
- Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
- Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
- Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
- Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
- Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing
About Equillium
(
Get Free Report)
Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.
Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
